Changing Cancer Care
Stanford scientists founded Filtricine after discovering a revolutionary way to starve cancer cells without harming the rest of the body. We are a clinical-stage biotechnology company dedicated to developing ground-breaking medical foods to manage cancer and improve lives of cancer patients around the world.
There is a Better Way:
A Scientific Breakthrough
Our founders discovered Targeted Nutrients Deprivation (TND) during their research at Stanford University. Cancer cells need multiple non-essential amino acids (NEAAs) to survive. Those NEAAs are found in all foods we eat. Our team found a way to formulate foods with NEAAs eliminated while preserving the nutrients our bodies need to thrive. Tality was created for cancer patients to regain control of their lives and get back to living their best life.
Positive Early Clinical Trial Results
Filtricine is sponsoring a clinical trial in prostate cancer patients at Stanford University School of Medicine, investigating Tality for the dietary management of cancer. Early clinical study results show Tality is nutritionally complete and safe to be consumed as the sole source of nutrition for cancer patients. Investigators found that “three (out of ten) participants experienced decrease in PSA (prostate-specific antigen); one participant experienced 32% decrease from baseline level of 107.9.” Read Poster Here. This clinical trial is ongoing. Tality is available to prostate cancer patients through this trial.
Additional Ways to Try Tality
If you are a cancer patient interested in Tality, we want to help. You can volunteer to try four-week supply of Tality at no cost. In the volunteer program, we ask for a few simple medical tests to monitor the health status of the patient and their cancer. All costs are covered by Filtricine.
We are excited to make our products available to more patients, and we welcome hearing from you.
Technology
Clinical Trial
Our Investors
Latest News
